{"classes":[{"categories":[{"measurements":[{"comment":"Could not be estimated due to the low number of events disease progression or death.","groupId":"OG000","lowerLimit":"2.0","upperLimit":"NA","value":"10.7"},{"comment":"Could not be estimated due to the low number of events disease progression or death.","groupId":"OG001","lowerLimit":"4.3","upperLimit":"NA","value":"8.0"},{"comment":"Could not be estimated due to the low number of events disease progression or death.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"22.0"},{"comment":"Could not be estimated due to the low number of events disease progression or death.","groupId":"OG003","lowerLimit":"9.1","upperLimit":"NA","value":"14.0"},{"comment":"Could not be estimated due to the low number of events disease progression or death.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"5.0"},{"groupId":"OG005","lowerLimit":"11.0","upperLimit":"17.1","value":"11.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"description":"Progression-free survival was defined as the time in weeks from date of first dose until the date of disease progression or death, whichever is earliest.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with the indication of ovarian cancer, received Tisotumab vedotin 1.2 mg/kg (the recommended dose for phase II trials \\[RP2D\\] from the Dose Escalation part), administered as an intravenous infusion, over a minimum of 30 minutes 3 times every 4 weeks (3q4wk).","id":"OG000","title":"Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian"},{"description":"Participants with the indication of ovarian cancer, received Tisotumab vedotin 1.2 mg/kg (the recommended dose for phase II trials \\[RP2D\\] from the Dose Escalation part), administered as an intravenous infusion, over a minimum of 30 minutes 3 times every 4 weeks (3q4wk).","id":"OG001","title":"Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical"},{"description":"Participants with the indication of ovarian cancer, received Tisotumab vedotin 1.2 mg/kg (RP2D from the Dose Escalation part), administered as an intravenous infusion, over a minimum of 30 minutes 3 times every 4 weeks (3q4wk). Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg, administered as an intravenous infusion once every 3 weeks (1q3w).","id":"OG002","title":"Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian"},{"description":"Participants with the indication of cervical cancer, received Tisotumab vedotin 1.2 mg/kg (RP2D from the Dose Escalation part), administered as an intravenous infusion, over a minimum of 30 minutes 3 times every 4 weeks (3q4wk). Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg, administered as an intravenous infusion once every 3 weeks (1q3w).","id":"OG003","title":"Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical"},{"description":"Participants with the indication of ovarian cancer, received Tisotumab vedotin 2.0 mg/kg, administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3w); the revised dose and schedule due to severe ocular toxicity.","id":"OG004","title":"Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian"},{"description":"Participants with the indication of cervical cancer, received Tisotumab vedotin 2.0 mg/kg, administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3w); the revised dose and schedule due to severe ocular toxicity.","id":"OG005","title":"Part 2: Cohort Expansion: Cohort 6 1q3w Cervical"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Baseline to end of trial (Part 2), up to 36 weeks","title":"Part 2: Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"weeks"}